Oxford spin-out seeks partner for cancer vaccine

Partnership opportunity

Oxford University biopharmaceutical spin-out, Oxford BioMedica, is looking for partnership to develop it’s Hi8 MEL therapeutic vaccine for metastatic melanoma.

“Oxford BioMedica is looking for a global partner with an oncology focus amongst big pharma and large biotech to co-develop and market the product,” said the Oxford BioMedica spokesperson.  

Hi-8 MEL is Oxford BioMedica’s therapeutic vaccine for metastatic melanoma. The product consists of two recombinant vectors, a plasmid DNA and a non-replicating Modified Vaccinia Ankara (MVA) virus. Both vectors encode the Mel3 polyepitope string derived from five different melanoma-associated antigens. Administration of the two recombinant vectors in a heterologous prime-boost format is designed to induce broad melanoma-specific CD8+ T-cell responses.

Oxford BioMedica is a biopharmaceutical company specialising in the development and commercialisation of novel therapeutic vaccines and gene-based therapies with a focus on oncology and neurotherapy. The Company was established in 1995 as a spin-out from Oxford University, and is listed on the London Stock Exchange.